NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26031155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Maiko Naito und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Tuberculosis, Pulmonary, Proteome, Phosphoproteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology(AMED-CREST), Japan Society for the Promotion of Science (JSPS) KAKENHI.
Abstract (Originalsprache)
Nontuberculous mycobacterial pulmonary disease (NTM-PD), mainly caused by Mycobacterium avium complex (MAC), and pulmonary tuberculosis (TB) are emerging health problems worldwide. However, because their clinical features are often similar, it remains difficult to differentiate NTM-PD from TB when the diagnosis cannot be made by sputum culture. To investigate potential serum biomarkers, we conducted non-targeted proteome analysis on serum extracellular vesicles (EVs) collected from 10 patients with MAC pulmonary disease (MAC-PD), 7 patients with TB, and 10 healthy controls. A total of 2614 proteins were identified in the discovery cohort. The EV protein signature from patients with NTM-PD and TB reflected infectious diseases and inflammatory response pathways. Among the identified proteins, the expression of Na+/H+ exchanger regulatory factor 2 (NHERF2) was significantly elevated in patients with MAC-PD compared with healthy controls and patients with TB. Moreover, upregulation of NHERF2 was confirmed by immunoblotting of serum EVs and immunohistochemistry of lungs with mycobacterial infection. Our findings highlight that NHERF2 in serum EVs might be a potential biomarker for distinguishing MAC-PD from TB, possibly reflecting the pathogenesis of MAC-PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
- Department of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan.
- Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka 565-0871, Japan.
- Department of Statistical Genetics, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
- Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa 230-0045, Japan.
- Department of Pathology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
ORCID-Profile: Maiko Naito, Satoshi Nojima, Mari Nogami-Ito, Yukihiro Yano, Takanori Matsuki, Makoto Yamamoto, Yujiro Naito, Kotaro Miyake, Koji Ueda
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology(AMED-CREST)
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Japan Agency for Medical Research and Development—Core Research for Evolutional Science and Technology (AMED–CREST)
- Cabinet Office of Japan Government for the Public/Private R&D Investment Strategic Expansion Program (PRISM)
- Uehara Memorial Foundation
- Nippon Foundation–Osaka University Project for Infectious Disease Prevention
- Japanese Respiratory Foundation (JRF)
Zitieren
APA
Naito, M., Takeda, Y., Edahiro, R., Shirai, Y., Enomoto, T., Nakayama, M., Nojima, S., Nogami-Ito, M., Mori, M., Yano, Y., Matsuki, T., Yoshimura, H., Hara, R., Yamamoto, M., Masuhiro, K., Naito, Y., Koyama, S., Iwahori, K., Nagatomo, I., …, & Kumanogoh, A. (2025). NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031155
Vancouver
Naito M, Takeda Y, Edahiro R, Shirai Y, Enomoto T, Nakayama M, et al. NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031155
BibTeX
@article{Naito2025,
author = {Naito, Maiko and Takeda, Yoshito and Edahiro, Ryuya and Shirai, Yuya and Enomoto, Takatoshi and Nakayama, Mana and Nojima, Satoshi and Nogami-Ito, Mari and Mori, Masahide and Yano, Yukihiro and Matsuki, Takanori and Yoshimura, Hanako and Hara, Reina and Yamamoto, Makoto and Masuhiro, Kentaro and Naito, Yujiro and Koyama, Shohei and Iwahori, Kota and Nagatomo, Izumi and Shiroyama, Takayuki and Miyake, Kotaro and Hirata, Haruhiko and Hase, Hiroaki and Tsujikawa, Kazutake and Ueda, Koji and Kumanogoh, Atsushi},
title = {NHERF2 as a Novel Biomarker for Distinguishing MAC Pulmonary Disease from Tuberculosis Based on Proteome Analysis of Serum Extracellular Vesicles},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26031155}
}
EUVIMED